NCT00204542View on ClinicalTrials.gov

Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head

PHASE4CompletedINTERVENTIONAL

Enrollment

418

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

March 31, 2009

Study Completion Date

December 31, 2010

Conditions

Photosensitivity Disorders

Interventions

DRUG

Diclofenac

Solaraze® (Diclofenac sodium) 2x/day topical for 3 months

DRUG

Diclofenac

Solaraze® (Diclofenac sodium) 2x/day topical for 6 months

Trial Locations (4)

10117

Klinik fuer Dermatologie, Venerologie und Allergologie der Charite, Berlin

72076

Skin Cancer Program, Department of Dermatology, Liebermeisterstrasse 8, Tübingen

79104

Dept. of Dermatology, Freiburg im Breisgau

Unknown

Praxis Priv.-Doz. Dr. med. Dirschka, Wuppertal

All Listed Sponsors

lead

University Hospital Tuebingen

OTHER

NCT00204542 - Comparison of the Efficacy and Tolerability of Solaraze for 3 Versus 6 Months in Patients With Mild to Moderate Actinic Keratosis Located on the Face and Head | Biotech Hunter | Biotech Hunter